

# Aiforia Technologies

## Company report

12/7/2023



**Antti Luuro**  
+358 50 571 4893  
antti.luuro@inderes.fi



**Frans-Mikael Rostedt**  
+358 44 327 0395  
frans-mikael.rostedt@inderes.fi

✓ Inderes corporate customer

This report is a summary translation of the report “Potentiaali houkuttelee palaamaan” published on 12/7/2023 at 9:10 am EET.

**inde  
res.**

# Potential tempts to get back on board

We lower our target price to EUR 4.2 (was 4.5) and raise our recommendation to Accumulate (was Reduce). We still see clear potential for Aiforia to grow into one of the long-term winners in its market, although weak growth predictability and elevated financing risks argue for caution in pricing the potential. The expansion of the use of the company's software in its customer base seems to be taking time and we cut our growth forecasts slightly. However, we believe that the decline in the share price (-24%) since our last report compensated sufficiently for the cuts, and at the current price we see the company's value creation potential outweighing the risks.

## Aiforia takes steps towards a strong position in a young but very attractive market

Aiforia's image recognition software is designed to provide faster, more efficient and precise analysis of pathological samples. The company already has a global customer base in medical research. The software has been rolled out to a much larger clinical customer base since the end of 2021. This market is emerging and Aiforia's competitive position looks good in light of the significant reference customers it has won (e.g. Mayo Clinic, NHS, Veneto). We see the company as having a strong initial position in the clinical market and promising potential to grow there to a significant size. With a strong healthcare customer base and high margins on the software, we see the market as very attractive. However, the visibility on the formation speed of the young market and the rate at which clinical players adopt AI solutions is so far weak.

## Strong scalable growth still on the horizon, although it will take time to ramp up customers

The ramp-up of the already won clinical customers, which are important for Aiforia's growth, continues to progress well, but we believe at a slower pace than our previous expectations. The company's main customer, Mayo Clinic, still has only one AI model in clinical use (Ki-67). For clients using ready-to-use models, roll-outs are progressing as expected (in Veneto and the first NHS hospital, models are estimated to be in place/going live). However, since the new EU regulation (CE-IVDR, 5/2022), Aiforia has not been able to get model approvals through due to a backlog of external notified body approvals. This in turn slows down certain customer expansions. For these reasons, we lowered our revenue forecasts by around 5-25% and earnings forecasts by around 0-30% for the coming years. Still, we expect Aiforia's growth to accelerate further between 2024 and 2027, with annual revenue growth expected to be a very strong 46-87% and EBIT margins to strengthen from a clearly loss-making investment phase to -5% in 2027. For 2030 we estimate a revenue of EUR 81 million (target: >100 MEUR ~2030). Our estimates require the company to gain a position among the winners of the clinical market. The financing of the company is not sufficient to cover the loss-making phase and we would see the raising of additional funding of around EUR 20 million at the beginning of 2025 at the latest as a sensible step. The forecast risks are very high, as it is not yet possible to obtain clear evidence of the company's growth rate.

## Despite the clear risks, we believe that the valuation again justifies further purchases

Aiforia's valuation (23-24e EV/S 30-19x, 25-26e 12-7x) relies on expectations of very strong and scalable growth. With methods that price growth at various rates and confidence intervals we can justify the company's value at a wide range of EUR 0.9-7.7 per share (previous EUR 0.9-7.5). Our confidence in the company's long-term growth is strong in the light of the evidence received. Risks are raised by the uncertainty of the growth rate and the need for additional financing, which we estimate the company will need by early 2025 at the latest. Supported by the company's good track record, we estimate that the dilution in a potential share issue would still be reasonable. As growth continues to strengthen, we see an attractive risk/return ratio at current share price.

## Recommendation

**Accumulate**


(previous Reduce)

**EUR 4.20**

(previous EUR 4.50)

**Share price:**

3.45



## Key figures

	2022	2023e	2024e	2025e
<b>Revenue</b>	1.9	2.7	5.1	9.0
<b>growth-%</b>	92%	46%	87%	75%
<b>EBIT adj.</b>	-10.2	-12.1	-12.0	-10.6
<b>EBIT-% adj.</b>	-546.2 %	-441.0 %	-235.3 %	-118.4 %
<b>Net Income</b>	-10.6	-12.2	-12.2	-10.9
<b>EPS (adj.)</b>	-0.41	-0.47	-0.46	-0.40

<b>P/E (adj.)</b>	neg.	neg.	neg.	neg.
<b>P/B</b>	2.8	5.3	16.3	neg.
<b>Dividend yield-%</b>	0.0 %	0.0 %	0.0 %	0.0 %
<b>EV/EBIT (adj.)</b>	neg.	neg.	neg.	neg.
<b>EV/EBITDA</b>	neg.	neg.	neg.	neg.
<b>EV/S</b>	32.9	30.3	19.1	12.2

Source: Inderes

## Guidance

(Unchanged)

The company has not issued a financial guidance for 2023.


## Share price



— Aiforia Technologies Oyj — OMXHCAP


Source: Millistream Market Data AB

## Revenue and EBIT-%



Source: Inderes

## EPS and dividend



Source: Inderes



## Value drivers

- Significant market potential in increasing automation in pathology
- Early evidence of the product's competitiveness
- Plenty of room for growth especially increasing the number of sample types supported by clinical customers and technology
- SaaS business model provides continuity and scalability as growth is successful
- Aiforia's attractiveness as an acquisition target in a highly valued sector



## Risk factors

- The business is only being built and the company's valuation virtually relies on future promises
- Falling behind ambitious objectives and drop in valuation that relies on successful strong growth
- Slower than expected progress in the implementation of new technology in a conservative industry, tightening regulations
- Competing technologies, changes in the company's position in the value chain of digital pathology, key personnel risks
- Data breach including personal health data
- Cash flow still strongly negative, which increases financing risk

Valuation	2023e	2024e	2025e
Share price	3.45	3.45	3.45
Number of shares, millions	26.0	26.4	27.2
Market cap	90	91	94
EV	83	98	110
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	5.3	16.3	neg.
P/S	32.7	17.8	10.5
EV/Sales	30.3	19.1	12.2
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

# Growth expectations lowered for the coming years

## Estimate revisions

- We lowered our revenue forecasts for the coming years, as the progress of Aiforia's software deployments looks slower than our previous expectations in the short term. In particular, the slower-than-expected pace of Mayo Clinic ramp-up and the backlog of the notified bodies performing CE-IVDR approvals will slow down the expansion in customers using ready-to-use models in the coming years.
- We made several revisions to Aiforia's cost forecasts. However, the decline in profitability forecasts was mainly due to the revenue cut. Due to the high gross margin on sales, this trickles down to profitability.
- We also revised our assumptions on option subscriptions and lowered our forecasts for share volume growth. As a result, forecasts of loss per share increased more than the decline in absolute earnings forecasts.
- Our long-term forecasts (2026-) changed more moderately, as we expect the ramp-up of Aiforia customers to continue to accelerate as getting approvals for ready-to-use models inevitably progresses in due course.

Estimate revisions MEUR / EUR	2023e			2024e			2025e		
	Old	New	Change %	Old	New	Change %	Old	New	Change %
Revenue	2.7	2.7	0%	5.6	5.1	-8%	11.7	9.0	-24%
EBITDA	-9.0	-9.0	0%	-7.3	-7.6	-5%	-3.5	-4.3	-24%
EBIT (exc. NRIs)	-12.1	-12.1	0%	-12.4	-12.0	3%	-9.8	-10.6	-9%
EBIT	-12.1	-12.1	0%	-12.4	-12.0	3%	-9.8	-10.6	-9%
PTP	-12.2	-12.2	0%	-12.6	-12.2	3%	-10.1	-10.9	-9%
EPS (excl. NRIs)	-0.46	-0.47	-2%	-0.44	-0.46	-5%	-0.30	-0.40	-31%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Source: Inderes

# Valuation in graphs


Estimated future valuation ranges,  
2024e and 2027e

2024e, MEUR	Low	High
Revenue	5.1	5.1
EV/S, LTM	20	30
EV/S, NTM	11.4	17.1
EV	102	153
Net cash	-7	-7
Market cap	96	147
Per share	3.6	5.6
Per share currently	3.1	4.8


2027e, MEUR	Low	High
Revenue	27.9	27.9
EV/S, LTM	8	12
EV/S, NTM	5.1	7.6
EV	223	335
Net cash	-24	-24
Market cap	199	311
Per share	7.2	11.3
Per share currently	4.2	6.6

Source: Inderes  
NTM = next 12 months  
LTM = last 12 months

Revenue development and terminal EBIT % of DCF scenarios  
MEUR and % of revenue



Sensitivity of the DCF value to the required return,  
EUR per share, WACC-%




Source: Inderes

# Valuation table

Valuation	2018	2019	2020	2021	2022	2023e	2024e	2025e	2026e
Share price				5.22	3.23	3.45	3.45	3.45	3.45
Number of shares, millions				25.8	25.8	26.0	26.4	27.2	27.5
Market cap				135	83	90	91	94	95
EV				99	61	83	98	110	119
P/E (adj.)				neg.	neg.	neg.	neg.	neg.	neg.
P/E				neg.	neg.	neg.	neg.	neg.	neg.
P/B				3.6	2.8	5.3	16.3	neg.	neg.
P/S				>100	44.7	32.7	17.8	10.5	5.7
EV/Sales					32.9	30.3	19.1	12.2	7.2
EV/EBITDA				neg.	neg.	neg.	neg.	neg.	neg.
EV/EBIT (adj.)				neg.	neg.	neg.	neg.	neg.	neg.
Payout ratio (%)				0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Dividend yield-%				0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Source: Inderes



# Peer group valuation

Peer group valuation	Market cap	EV	EV/EBIT		EV/EBITDA		EV/S		Revenue growth-%		EBIT-%		Rule of 40
Company	MEUR	MEUR	2023e	2024e	2023e	2024e	2023e	2024e	2023e	2024e	2023e	2024e	2024e
Sectra AB	2354	2289	57.5	52.2	50.7	43.1	11.1	9.7	23%	14%	19%	19%	33%
ContextVision AB	52	47	10.9	11.5	9.2	8.5	3.9	3.7	19%	5%	36%	32%	37%
Roche Holding AG	216829	241054	11.6	10.8	9.9	9.3	3.8	3.6	-6%	4%	33%	34%	38%
INIFY Laboratories AB									0%	0%	0%	0%	0%
Feedback PLC	11	3					2.3	1.5	67%	48%	-428%	-213%	-165%
PainChek Ltd	37	35					10.0	6.7	93%	50%	-59%	-22%	28%
Renalytix PLC	20	8					2.3	1.3	-9%	72%		-531%	
Diagnos Inc	23	25					61.3	24.5	20%	150%			
CellaVision AB	356	356	27.3	20.3	21.5	16.9	6.2	5.4	-3%	15%	23%	27%	42%
RaySearch Laboratories AB	299	317	29.1	20.2	8.8	7.4	3.5	3.2	26%	11%	12%	16%	27%
<b>Aiforia Technologies Oyj (Inderes)</b>	<b>90</b>	<b>83</b>	<b>-6.9</b>	<b>-8.1</b>	<b>-9.3</b>	<b>-12.8</b>	<b>30.3</b>	<b>19.1</b>	<b>46%</b>	<b>87%</b>	<b>-441%</b>	<b>-235%</b>	<b>-148%</b>
<b>Average</b>			<b>27.3</b>	<b>23.0</b>	<b>20.0</b>	<b>17.0</b>	<b>11.6</b>	<b>6.6</b>	<b>23%</b>	<b>37%</b>	<b>-46%</b>	<b>-71%</b>	
<b>Median</b>	<b>36.8</b>	<b>35.3</b>	<b>27.3</b>	<b>20.2</b>	<b>9.9</b>	<b>9.3</b>	<b>3.9</b>	<b>3.7</b>	<b>20%</b>	<b>15%</b>	<b>16%</b>	<b>16%</b>	<b>35%</b>
<b>Diff.% to median</b>	<b>143%</b>	<b>135%</b>	<b>-125%</b>	<b>-140%</b>	<b>-194%</b>	<b>-238%</b>	<b>678%</b>	<b>415%</b>	<b>138%</b>	<b>499%</b>			<b>-524%</b>

Source: Refinitiv / Inderes

# Income statement

Income statement	H1'21	H2'21	2021	H1'22	H2'22	2022	H1'23	H2'23e	2023e	2024e	2025e	2026e
Revenue	0.4	0.5	1.0	0.7	1.1	1.9	0.9	1.8	2.7	5.1	9.0	16.5
EBITDA	-1.3	-2.2	-3.5	-3.5	-4.6	-8.1	-4.9	-4.1	-9.0	-7.6	-4.3	-1.3
Depreciation	-0.6	-0.7	-1.2	-0.9	-1.2	-2.1	-1.3	-1.7	-3.1	-4.4	-6.3	-7.4
EBIT (excl. NRI)	-1.9	-2.8	-4.7	-4.4	-5.8	-10.2	-6.2	-5.9	-12.1	-12.0	-10.6	-8.6
EBIT	-1.9	-2.8	-4.7	-4.4	-5.8	-10.2	-6.2	-5.9	-12.1	-12.0	-10.6	-8.6
Net financial items	-0.5	-2.4	-2.9	0.0	-0.4	-0.4	-0.1	-0.1	-0.2	-0.2	-0.3	-0.3
PTP	-2.3	-5.2	-7.6	-4.4	-6.2	-10.6	-6.3	-6.0	-12.2	-12.2	-10.9	-8.9
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	-2.3	-5.2	-7.6	-4.4	-6.2	-10.6	-6.3	-6.0	-12.2	-12.2	-10.9	-8.9
EPS (adj.)				-0.17	-0.24	-0.41	-0.24	-0.23	-0.47	-0.46	-0.40	-0.32
EPS (rep.)				-0.17	-0.24	-0.41	-0.24	-0.23	-0.47	-0.46	-0.40	-0.32

Key figures	H1'21	H2'21	2021	H1'22	H2'22	2022	H1'23	H2'23e	2023e	2024e	2025e	2026e
Revenue growth-%	-4.3 %		14.7 %	72.1 %	107.1 %	91.8 %	25.5 %	60.0 %	46.5 %	86.9 %	75.3 %	83.9 %
Adjusted EBIT growth-%	53.7 %		78.1 %	137.2 %	104.8 %	117.6 %	40.9 %	1.2 %	18.2 %	-0.3 %	-11.7 %	-18.8 %
EBITDA-%	-299.8 %	-396.5 %	-354.2 %	-479.1 %	-405.0 %	-434.1 %	-530.0 %	-227.8 %	-329.5 %	-148.8 %	-48.1 %	-7.6 %
Adjusted EBIT-%	-434.3 %	-518.1 %	-481.4 %	-598.8 %	-512.2 %	-546.2 %	-672.0 %	-323.9 %	-441.0 %	-235.3 %	-118.4 %	-52.3 %
Net earnings-%	-550.0 %	-954.7 %	-777.7 %	-597.6 %	-548.6 %	-567.8 %	-679.8 %	-330.0 %	-447.6 %	-239.2 %	-121.8 %	-54.1 %

Source: Inderes

# Balance sheet

Assets	2021	2022	2023e	2024e	2025e
<b>Non-current assets</b>	<b>4.8</b>	<b>9.1</b>	<b>12.7</b>	<b>15.4</b>	<b>16.4</b>
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	4.7	8.4	11.7	14.0	14.7
Tangible assets	0.1	0.5	1.0	1.4	1.7
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.1	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
<b>Current assets</b>	<b>39.1</b>	<b>26.3</b>	<b>13.5</b>	<b>4.1</b>	<b>2.0</b>
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	1.0	1.6	1.4	1.5	2.0
Cash and equivalents	38.1	24.7	12.2	2.6	0.0
<b>Balance sheet total</b>	<b>43.9</b>	<b>35.3</b>	<b>26.2</b>	<b>19.6</b>	<b>18.3</b>


Source: Inderes

Liabilities & equity	2021	2022	2023e	2024e	2025e
<b>Equity</b>	<b>37.8</b>	<b>29.3</b>	<b>17.0</b>	<b>5.6</b>	<b>-3.1</b>
Share capital	0.1	0.1	0.1	0.1	0.1
Retained earnings	-17.7	-28.4	-40.6	-52.9	-63.8
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	55.5	57.6	57.6	58.3	60.5
Minorities	0.0	0.0	0.0	0.0	0.0
<b>Non-current liabilities</b>	<b>2.7</b>	<b>2.2</b>	<b>5.7</b>	<b>9.4</b>	<b>14.4</b>
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	2.7	2.2	5.7	9.4	14.4
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
<b>Current liabilities</b>	<b>3.3</b>	<b>3.9</b>	<b>3.5</b>	<b>4.7</b>	<b>7.1</b>
Interest bearing debt	0.2	0.5	0.0	0.0	1.3
Payables	2.4	2.0	2.2	3.3	4.5
Other current liabilities	0.7	1.3	1.3	1.3	1.3
<b>Balance sheet total</b>	<b>43.9</b>	<b>35.3</b>	<b>26.2</b>	<b>19.6</b>	<b>18.3</b>

# DCF calculation

DCF model	2022	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	TERM
Revenue growth-%	91.8 %	46.5 %	86.9 %	75.3 %	83.9 %	69.2 %	56.9 %	39.1 %	33.5 %	23.0 %	18.0 %	12.0 %	9.0 %	6.0 %	5.0 %	2.5 %	2.5 %
EBIT-%	-546.2 %	-441.0 %	-235.3 %	-118.4 %	-52.3 %	-4.8 %	11.6 %	19.8 %	24.6 %	29.0 %	34.0 %	32.0 %	30.0 %	28.0 %	28.0 %	28.0 %	28.0 %
<b>EBIT (operating profit)</b>	<b>-10.2</b>	<b>-12.1</b>	<b>-12.0</b>	<b>-10.6</b>	<b>-8.6</b>	<b>-1.3</b>	<b>5.1</b>	<b>12.1</b>	<b>20.0</b>	<b>29.0</b>	<b>40.1</b>	<b>42.3</b>	<b>43.2</b>	<b>42.8</b>	<b>44.9</b>	<b>46.0</b>	
+ Depreciation	2.1	3.2	4.4	6.3	7.4	8.0	9.0	10.1	11.1	11.3	11.4	11.4	11.4	11.4	11.4	11.4	
- Paid taxes	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	2.0	1.4	-6.2	-8.4	-8.6	-8.5	-8.9	-9.2	
- Tax, financial expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1	-0.1	-0.1	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	-0.3	0.4	1.0	0.7	1.1	2.0	3.2	3.4	4.1	3.7	3.6	2.8	2.4	1.7	1.5	0.8	
<b>Operating cash flow</b>	<b>-8.5</b>	<b>-8.5</b>	<b>-6.6</b>	<b>-3.6</b>	<b>-0.1</b>	<b>8.6</b>	<b>18.2</b>	<b>27.4</b>	<b>37.2</b>	<b>45.5</b>	<b>48.9</b>	<b>48.1</b>	<b>48.4</b>	<b>47.3</b>	<b>48.9</b>	<b>49.0</b>	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-6.4	-6.8	-7.2	-7.2	-7.9	-8.6	-9.4	-10.3	-11.3	-11.3	-11.4	-11.4	-11.4	-11.4	-11.4	-11.2	
<b>Free operating cash flow</b>	<b>-14.8</b>	<b>-15.3</b>	<b>-13.8</b>	<b>-10.8</b>	<b>-8.0</b>	<b>0.0</b>	<b>8.8</b>	<b>17.1</b>	<b>25.9</b>	<b>34.2</b>	<b>37.5</b>	<b>36.7</b>	<b>37.0</b>	<b>36.0</b>	<b>37.5</b>	<b>37.8</b>	
+/- Other	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	-12.7	-15.3	-13.8	-10.8	-8.0	0.0	8.8	17.1	25.9	34.2	37.5	36.7	37.0	36.0	37.5	37.8	343
<b>Discounted FCFF</b>		<b>-15.2</b>	<b>-12.1</b>	<b>-8.3</b>	<b>-5.4</b>	<b>0.0</b>	<b>4.6</b>	<b>7.8</b>	<b>10.4</b>	<b>12.0</b>	<b>11.6</b>	<b>10.0</b>	<b>8.8</b>	<b>7.5</b>	<b>6.9</b>	<b>6.1</b>	<b>55.5</b>
Sum of FCFF present value		100	116	128	136	141	141	137	129	119	107	94.9	84.9	76.1	68.6	61.7	55.5
<b>Enterprise value DCF</b>		<b>100</b>															
- Interest bearing debt		-2.7															
+ Cash and cash equivalents		24.7															
- Minorities		0.0															
- Dividend/capital return		0.0															
<b>Equity value DCF</b>		<b>122</b>															
<b>Equity value DCF per share</b>		<b>4.7</b>															

Cash flow distribution



WACC	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E))	5.0 %
Cost of debt	6.0 %
Equity Beta	1.85
Market risk premium	4.75%
Liquidity premium	3.00%
Risk free interest rate	2.5 %
<b>Cost of equity</b>	<b>14.3 %</b>
<b>Weighted average cost of capital (WACC)</b>	<b>13.8 %</b>

Source: Inderes

# Summary

Income statement	2020	2021	2022	2023e	2024e	Per share data	2020	2021	2022	2023e	2024e
Revenue	0.8	1.0	1.9	2.7	5.1	EPS (reported)			-0.41	-0.47	-0.46
EBITDA	-1.6	-3.5	-8.1	-8.9	-7.6	EPS (adj.)			-0.41	-0.47	-0.46
EBIT	-2.6	-4.7	-10.2	-12.1	-12.0	OCF / share			-0.33	-0.33	-0.25
PTP	-2.8	-7.6	-10.6	-12.2	-12.2	FCF / share			-0.49	-0.59	-0.53
Net Income	-2.8	-7.6	-10.6	-12.2	-12.2	Book value / share			1.13	0.66	0.21
Extraordinary items	0.0	0.0	0.0	0.0	0.0	Dividend / share			0.00	0.00	0.00
Balance sheet	2020	2021	2022	2023e	2024e	Growth and profitability	2020	2021	2022	2023e	2024e
Balance sheet total	5.3	43.9	35.3	26.2	19.6	Revenue growth-%	33%	15%	92%	46%	87%
Equity capital	0.9	37.8	29.3	17.0	5.6	EBITDA growth-%	-25%	114%	135%	10%	-14%
Goodwill	0.0	0.0	0.0	0.0	0.0	EBIT (adj.) growth-%	-13%	78%	118%	18%	0%
Net debt	1.3	-35.2	-22.0	-6.5	6.8	EPS (adj.) growth-%				15%	-2%
Cash flow	2020	2021	2022	2023e	2024e	EBITDA-%	-189.8 %	-354.2 %	-434.1 %	-324.8 %	-148.8 %
EBITDA	-1.6	-3.5	-8.1	-8.9	-7.6	EBIT (adj.)-%	-310.1 %	-481.4 %	-546.2 %	-441.0 %	-235.3 %
Change in working capital	-1.2	2.1	-0.3	0.4	1.0	EBIT-%	-310.1 %	-481.4 %	-546.2 %	-441.0 %	-235.3 %
Operating cash flow	-2.8	-1.4	-8.5	-8.5	-6.6	ROE-%	-386.3 %	-39.1 %	-31.6 %	-52.9 %	-108.2 %
CAPEX	-0.8	-3.8	-6.4	-6.8	-7.2	ROI-%	-77.0 %	-20.9 %	-28.1 %	-44.1 %	-64.0 %
Free cash flow	-3.6	-5.2	-12.7	-15.3	-13.8	Equity ratio	16.8 %	86.3 %	82.9 %	65.0 %	28.5 %
Valuation multiples	2020	2021	2022	2023e	2024e	Gearing	146.0 %	-93.0 %	-75.1 %	-38.3 %	121.4 %
EV/S			32.9	30.3	19.1						
EV/EBITDA (adj.)			neg.	neg.	neg.						
EV/EBIT (adj.)			neg.	neg.	neg.						
P/E (adj.)			neg.	neg.	neg.						
P/B			2.8	5.3	16.3						
Dividend-%			0.0 %	0.0 %	0.0 %						

Source: Inderes

# Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at [www.inderes.fi/research-disclaimer](http://www.inderes.fi/research-disclaimer).

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

## Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
6/24/2022	Sell	4.00 €	4.58 €
8/26/2022	Reduce	4.00 €	3.52 €
12/3/2022	Reduce	4.00 €	3.50 €
3/3/2023	Accumulate	4.80 €	4.15 €
8/28/2023	Reduce	4.50 €	4.54 €
12/7/2023	Accumulate	4.20 €	3.45 €



**Inderes democratizes investor information by connecting investors and listed companies.**

We help over 400 listed companies better serve investors. Our investor community is home to over 70,000 active members.

We build solutions for listed companies that enable frictionless and effective investor relations. For listed companies, we offer Commissioned Research, IR Events, AGMs, and IR Software.

Inderes is listed on the Nasdaq First North growth market and operates in Finland, Sweden, Norway, and Denmark.

**Inderes Oyj**

Itämerentori 2

FI-00180 Helsinki, Finland

+358 10 219 4690

Award-winning research at [inderes.fi](https://www.inderes.fi)



**STARMINE  
ANALYST AWARDS  
FROM REFINITIV**



THOMSON REUTERS  
ANALYST AWARDS



Juha Kinnunen  
2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen  
2014, 2016, 2017, 2019



Sauli Vilén  
2012, 2016, 2018, 2019, 2020



Antti Viljakainen  
2014, 2015, 2016, 2018, 2019, 2020



Olli Koponen  
2020



Joni Grönqvist  
2019, 2020



Erkki Vesola  
2018, 2020



Petri Gostowski  
2020



Atte Riikola  
2020

**Connecting investors  
and listed companies.**